Clinical trials: Intravenous Infusions
Healthy Adult Male
A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects
To determine the mass balance of totalradioactivity following a single IV infusionof (14C)-OPC-61815. To determine routes and rates of elimination of total radioactivity following a single IV infusion of (14C)-OPC-61815 To assess…
- Trial name
- NCT04182958
- Testing
- (14C)-OPC-61815
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy
A Study in Healthy Men to Compare 2 Different Formulations of Alteplase
To establish the bioequivalence of alteplase derived from two different manufacturing processes.
- Trial name
- NCT04419493
- Testing
- Alteplase (from modified manufacturing process), Alteplase (from current manufacturing process), Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acute Respiratory Distress Syndrome
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
Recent COVID 19 pandemic has overwhelmed health services all around the world, and humanity has yet to find a cure or a vaccine for the treatment of patients, mainly the severe ones, who pose a therapeutic challenge to healthcare…
- Trial name
- NCT04390152
- Testing
- Wharton's jelly derived Mesenchymal stem cells.
- Where
- 2 sites in Colombia
- Volunteers
- 6 people
- Sponsor
- BioXcellerator
Antithrombin Deficiency, Congenital
Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.
Patients with hereditary antithrombin (AT) deficiency are at increased risk of venous thrombosis and pulmonary embolism, particularly during certain high risk procedures.
- Trial name
- rhAT (NCT00056550)
- Testing
- Recombinant Human Antithrombin (rhAT)
- Where
- 11 sites in United States, France and 4 more
- Volunteers
- 14 people
- Sponsor
- rEVO Biologics
Healthy
A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.
The purpose of this First-in-Human study is to evaluate the safety , tolerability and pharmacokinetics after single ascending of HNC042 given to healthy subjects, compared to placebo.
- Trial name
- NCT03740555
- Testing
- HNC042 single dose, HNC042 multiple ascending doses
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
This is a multicenter, parallel-group, double-blind, randomized phase 4 study designed to identify the optimal dose of CE1226 (2 active doses) to slow disease progression as assessed by reduced rates of annual lung density…
- Conditions
- Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema
- Trial name
- NCT07326592
- Testing
- CE1226
- Where
- 2 sites in Denmark
- Volunteers
- 270 people
- Sponsor
- CSL Behring
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric…
- Trial name
- NCT07043400
- Testing
- Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin
- Where
- 95 sites in United States, Argentina and 14 more
- Volunteers
- 351 people
- Sponsor
- BeOne Medicines
Edema
Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers
1. To investigate the safety and tolerability of Xerecept during and following a 24-hour intravenous administration to healthy Japanese to healthy Japanese and Caucasian subjects 2.
- Trial name
- NCT00820092
- Testing
- Xerecept 1.0, Xerecept 2.0, Xerecept 3.0
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Celtic Pharma Development Services
Advanced Solid Tumors
Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors
This is a Phase I dose escalation study of TCD-717, a novel drug that is a specific inhibitor of the enzyme choline kinase alpha, in patients with advanced solid tumors.
- Trial name
- NCT01215864
- Testing
- TCD-717
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Traslational Cancer Drugs Pharma, SL
Acute Ischemic Stroke AIS
A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS
This is a Phase IIa clinical trial with a three-arm design that utilizes randomization, double-blinding, and placebo control. The primary objective of this study is to evaluate the efficacy of single and multiple intravenous…
- Trial name
- NCT07084012
- Testing
- hUC-MSCs treatment (high dose), hUC-MSCs treatment (low dose)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Wingor Biotechnology Co., Ltd.
Healthy
Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female Volunteers
The objective of the present study was to obtain information about the safety, tolerability and pharmacokinetics of BIIR 561 CL after continuous intravenous administration of two increasing doses in healthy elderly volunteers…
- Trial name
- NCT02223507
- Testing
- BIIR 561 CL
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Corona Virus Infection, Covid19
Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
This is an interventional new drug clinical trial for a Phase 2 randomized, double-blind, and placebo control study using intravenous injection of allogeneic adipose stem cells (Celltex AdMSCs) for subjects with severe COVID-19.
- Trial name
- AdMSCs (NCT05017298)
- Testing
- Allogeneic adipose-derived stem cells
- Volunteers
- 30 people
- Sponsor
- Celltex Therapeutics Corporation
Sedation in Intensive Care
A Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Mechanical Ventilation
This is a multi-center, randomized, single-blind, propofol-controlled phase III clinical study. In this study, ICU patients undergoing mechanical ventilation are expected to be enrolled and will be randomly assigned to the…
- Trial name
- NCT04620031
- Testing
- HSK3486, Propofol
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Community-acquired Pneumonia
A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of intravenous nemonoxacin compared with intravenous moxifloxacin in adult patients with community-acquired pneumonia (CAP).
- Trial name
- NCT02205112
- Testing
- Nemonoxacin, Levofloxacin
- Where
- 63 sites in China, Taiwan
- Volunteers
- 598 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Cognitive Dysfunction
Efficacy and Safety of Cytoflavin® Used in Elderly Patients for the Prevention of Cognitive Decline After Major Surgery
Postoperative cognitive impairment develops in the early and continues in the late postoperative period; it is manifested by impaired memory, attention, concentration and other higher cortical functions (thinking, speech).
- Trial name
- NCT03849664
- Testing
- Cytoflavin® solution, Cytoflavin® enteric-coated tablet
- Where
- 13 sites in Russia
- Volunteers
- 200 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Sepsis, Bacteriemia
Safety and Efficacy of Immages System in Patients Recieving IV Therapy
The study will evaluate the functionality of IMMAGES , an intravenous infusion device system, in patients hospitalized in Bait Balev hospital.
- Conditions
- Sepsis, Bacteriemia, CHF
- Trial name
- IV (NCT02020811)
- Testing
- Sentinel
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- PRo-IV
Neoplasms
A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.
This 3 arm study will determine the dose of R1507 which will achieve a mean drug exposure in children and adolescents with advanced solid tumors equivalent to the exposure achieved in adults at the recommended dose of…
- Trial name
- NCT00560144
- Testing
- RG1507
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Graft Versus Host Disease
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients undergoing AHSCT, with radiation or non-radiation…
- Trial name
- NCT01379209
- Testing
- RGI-2001, Calcineurin Inhibitors, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- 6 sites in United States
- Volunteers
- 68 people
- Sponsor
- Regimmune Corporation
Dry Eye Syndrome, Systemic Lupus Erythematosus
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Sjorgren's disease (SjD) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary…
- Trial name
- NCT06977724
- Testing
- ABBV-319
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- AbbVie
Mitochondrial Diseases, Pearson Syndrome
Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)
Primary Mitochondrial diseases are a clinically and genetically heterogeneous group of disorders caused by mutations in genes encoded by nuclear Deoxyribonucleic Acid (DNA) or by mutations and/or deletions in the mitochondrial…
- Trial name
- NCT06017869
- Testing
- MNV-201
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- Minovia Therapeutics Ltd.